Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor

@article{Montgomery2007EndothelinRB,
  title={Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor},
  author={Jennifer P Montgomery and Paul H. Patterson},
  journal={BMC Cancer},
  year={2007},
  volume={8},
  pages={354 - 354}
}
Endothelin receptor antagonists inhibit the progression of many cancers, but research into their influence on glioma has been limited. We treated glioma cell lines, LN-229 and SW1088, and melanoma cell lines, A375 and WM35, with two endothelin receptor type B (ETRB)-specific antagonists, A-192621 and BQ788, and quantified viable cells by the capacity of their intracellular esterases to convert non-fluorescent calcein AM into green-fluorescent calcein. We assessed cell proliferation by labeling… CONTINUE READING